Company profile for Aim ImmunoTech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aim ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the h...
Aim ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2117 SW Highway 484 Ocala, FL 34473
Telephone
Telephone
352-448-7797
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/10/3203214/29489/en/AIM-ImmunoTech-Announces-Release-of-the-Next-CEO-Corner-Segment.html

GLOBENEWSWIRE
10 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3197061/29489/en/AIM-ImmunoTech-to-Participate-in-Live-Fireside-Chat-on-Virtual-Investor-Closing-Bell-Series.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/18/3190059/29489/en/AIM-ImmunoTech-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Continued-Progress-Across-Pipeline-with-Strategic-Focus-on-Pancreatic-Cancer-Clinical-Program.html

GLOBENEWSWIRE
18 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3184613/29489/en/AIM-ImmunoTech-Details-New-UPMC-Abstract-on-Completed-Clinical-Trial-Involving-Ampligen-s-Synergistic-Potential-in-the-Treatment-of-Advanced-Recurrent-Ovarian-Cancer.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180447/29489/en/AIM-ImmunoTech-Announces-Late-Breaking-Abstract-from-University-of-Pittsburgh-Medical-Center-Accepted-for-Presentation-at-the-40th-Annual-Society-for-Immunotherapy-of-Cancer-SITC-M.html

GLOBENEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179326/29489/en/AIM-ImmunoTech-Announces-European-Patent-Office-Grants-Patent-Covering-Ampligen-Rintatolimod-for-Use-in-the-Treatment-of-the-Post-COVID-Condition-of-Fatigue.html

GLOBENEWSWIRE
03 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty